These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25894259)

  • 1. [The treatment of diabetes in patients with liver and renal impairment].
    Haluzík M
    Vnitr Lek; 2015 Apr; 61(4):304-11. PubMed ID: 25894259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of oral glucose-lowering agents in patients with renal impairment].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.
    Tschöpe D; Hanefeld M; Meier JJ; Gitt AK; Halle M; Bramlage P; Schumm-Draeger PM
    Cardiovasc Diabetol; 2013 Apr; 12():62. PubMed ID: 23574917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA; D'Elia JA; Finn P; Lewis EF; Desai AS; Claggett BL; Cooper ME; McGill JB
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
    Scheen AJ
    Rev Med Liege; 2013 Apr; 68(4):190-5. PubMed ID: 23755710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic kidney diseases, metformin and lactic acidosis].
    Borbély Z
    Vnitr Lek; 2016 Apr; 62(4):299-303. PubMed ID: 27250607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.
    Zanchi A; Lehmann R; Philippe J
    Swiss Med Wkly; 2012; 142():w13629. PubMed ID: 22987488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
    Harrower AD
    Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antidiabetic agents and renal insufficiency].
    Robles NR; Blanco J
    Nefrologia; 2002; 22(4):325-8. PubMed ID: 12369123
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
    Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
    Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glucose lowering drugs in case of impaired renal function].
    Assink MA; Abrahams AC; Rookmaaker MB
    Ned Tijdschr Geneeskd; 2014; 158():A6907. PubMed ID: 24618238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving glycemic control in patients with type 2 diabetes and renal impairment.
    Avogaro A; Schernthaner G
    Acta Diabetol; 2013 Jun; 50(3):283-91. PubMed ID: 23212669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.